We recently reported that alpha-2 macroglobulin (A2M) is a biomarker of neuronal injury in Alzheimer’s disease (AD) and identified a network of nine genes co-expressed with A2M in the brain. This network includes the gene encoding SPARCL1, a protein implicated in synaptic maintenance. Here, we examine whether SPARCL1 is associated with longitudinal changes in brain structure and function in older individuals at risk for AD in the Baltimore Longitudinal Study of Aging. Using data from the Gene-Tissue Expression Project, we first identified two single nucleotide polymorphisms (SNPs), rs9998212 and rs7695558, associated with lower brain SPARCL1 gene expression. We then analyzed longitudinal trajectories of cognitive performance in 591 participants who remained cognitively normal (average follow-up interval: 11.8 years) and 129 subjects who eventually developed MCI or AD (average follow-up interval: 9.4 years). Cognitively normal minor allele carriers of rs7695558 who developed incident AD showed accelerated memory loss prior to disease onset. Next, we compared longitudinal changes in brain volumes (MRI; n = 120 participants; follow-up = 6.4 years; 826 scans) and resting-state cerebral blood flow (rCBF; 15O-water PET; n = 81 participants; follow-up = 7.7 years; 664 scans) in cognitively normal participants. Cognitively normal minor allele carriers of rs9998212 showed accelerated atrophy in several global, lobar, and regional brain volumes. Minor allele carriers of both SNPs showed longitudinal changes in rCBF in several brain regions, including those vulnerable to AD pathology. Our findings suggest that SPARCL1 accelerates AD pathogenesis and thus link neuroinflammation with widespread changes in brain structure and function during aging.
RyanNS, RossorMN, FoxNC (2015) Alzheimer’s disease in the 100 years since Alzheimer’s death. Brain138, 3816–3821.
2.
SkaperSD (2012) Alzheimer’s disease and amyloid: Culprit or coincidence?Int Rev Neurobiol102, 277–316.
3.
IqbalK, LiuF, GongCX (2014) Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles. Biochem Pharmacol88, 631–639.
4.
IsingC, StanleyM, HoltzmanDM (2015) Current thinking on the mechanistic basis of Alzheimer’s and implications for drug development. Clin Pharmacol Ther98, 469–471.
McCaulleyME, GrushKA (2015) Alzheimer’s disease: Exploring the role of inflammation and implications for treatment. Int J Alzheimers Dis2015, 515248.
7.
VarmaVR, VarmaS, AnY, HohmanTJ, SeddighiS, CasanovaR, BeriA, DammerEB, SeyfriedNT, PletnikovaO, MoghekarA, WilsonMR, LahJJ, O’BrienRJ, LeveyAI, TroncosoJC, AlbertMS, ThambisettyM (2017) Alpha-2 macroglobulin in Alzheimer’s disease: A marker of neuronal injury through the RCAN1 pathway. Mol Psychiatry22, 13–23.
8.
KucukdereliH, AllenNJ, LeeAT, FengA, OzluMI, ConatserLM, ChakrabortyC, WorkmanG, WeaverM, SageEH, BarresBA, ErogluC (2011) Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc Natl Acad Sci U S A108, E440–E449.
9.
ErogluC (2009) The role of astrocyte-secreted matricellular proteins in central nervous system development and function. J Cell Commun Signal3, 167–176.
10.
JonesEV, BouvierDS (2014) Astrocyte-secreted matricellular proteins in CNS remodelling during development and disease. Neural Plast2014, 321209.
11.
McKinnonPJ, MargolskeeRF (1996) SC1: A marker for astrocytes in the adult rodent brain is upregulated during reactive astrocytosis. Brain Res709, 27–36.
12.
PurcellAE, JeonOH, ZimmermanAW, BlueME, PevsnerJ (2001) Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology57, 1618–1628.
13.
HammackBN, FungKY, HunsuckerSW, DuncanMW, BurgoonMP, OwensGP, GildenDH (2004) Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler10, 245–260.
14.
JacquemontML, SanlavilleD, RedonR, RaoulO, Cormier-DaireV, LyonnetS, AmielJ, Le MerrerM, HeronD, de BloisMC, PrieurM, VekemansM, CarterNP, MunnichA, ColleauxL, PhilippeA (2006) Array-based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders. J Med Genet43, 843–849.
15.
KählerAK, DjurovicS, KulleB, JönssonEG, AgartzI, HallH, OpjordsmoenS, JakobsenKD, HansenT, MelleI, WergeT, SteenVM, AndreassenOA (2008) Association analysis of schizophrenia on 18 genes involved in neuronal migration: MDGA1 as a new susceptibility gene. Am J Med Genet B Neuropsychiatr Genet147B, 1089–1100.
ZhurovV, SteadJD, MeraliZ, PalkovitsM, FaludiG, Schild-PoulterC, AnismanH, PoulterMO (2012) Molecular pathway reconstruction and analysis of disturbed gene expression in depressed individuals who died by suicide. PLoS One7, e47581.
YinGN, LeeHW, ChoJY, SukK (2009) Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res1265, 158–170.
20.
Vafadar-IsfahaniB, BallG, CoveneyC, LemetreC, BoocockD, MinthonL, HanssonO, MilesAK, JanciauskieneSM, WardenD, SmithAD, WilcockG, KalshekerN, ReesR, Matharoo-BallB, MorganK (2012) Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer’s disease in cerebrospinal fluid. J Alzheimers Dis28, 625–636.
21.
RichensJL, VereKA, LightRA, SoriaD, GaribaldiJ, SmithAD, WardenD, WilcockG, BajajN, MorganK, O’SheaP (2014) Practical detection of a definitive biomarker panel for Alzheimer’s disease; comparisons between matched plasma and cerebrospinal fluid. Int J Mol Epidemiol Genet5, 53–70.
VarmaS (2015) Network model of normal gene expression predicts gene perturbation fold changes. 8th Annual RECOMB/ISCB Conference on Regulatory and Systems Genomics with DREAM Challenges 2015, Philadelphia, PA, pp. 78–79.
TerraccianoA, BalaciL, ThayerJ, ScallyM, KokinosS, FerrucciL, TanakaT, ZondermanAB, SannaS, OllaN, ZunchedduMA, NaitzaS, BusoneroF, UdaM, SchlessingerD, AbecasisGR, CostaPTJr (2009) Variants of the serotonin transporter gene and NEO-PI-R Neuroticism: No association in the BLSA and SardiNIA samples. Am J Med Genet B Neuropsychiatr Genet150B, 1070–1077.
30.
StoneJL, NorrisAH (1966) Activities and attitudes of participants in the Baltimore longitudinal study. J Gerontol21, 575–580.
31.
FabbriE, AnY, ZoliM, TanakaT, SimonsickEM, Kitner-TrioloMH, StudenskiSA, ResnickSM, FerrucciL (2016) Association between accelerated multimorbidity and age-related cognitive decline in older Baltimore Longitudinal Study of Aging participants without dementia. J Am Geriatr Soc64, 965–972.
32.
PetersenRC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med256, 183–194.
33.
WilliamsJ (1987) American Psychiatric Association, Washington, DC.
34.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
35.
BlessedG, TomlinsonBE, RothM (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry114, 797–811.
36.
MorrisJC (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr9(Suppl 1), 173–176; discussion 177–178.
37.
RadloffLS (1991) The use of the Center for Epidemiologic Studies Depression Scale in adolescents and young adults. J Youth Adolesc20, 149–166.
38.
FerrucciL (2008) The Baltimore Longitudinal Study of Aging (BLSA): A 50-year-long journey and plans for the future. J Gerontol A Biol Sci Med Sci63, 1416–1419.
39.
ShockNW, Gerontology Research Center (U.S.) (1984) Normal human aging: The Baltimore Longitudinal Study of Aging, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Aging For sale by the Supt. of Docs., U.S. G.P.O., Baltimore, Md. Washington, D.C.
40.
ResnickSM, GoldszalAF, DavatzikosC, GolskiS, KrautMA, MetterEJ, BryanRN, ZondermanAB (2000) One-year age changes in MRI brain volumes in older adults. Cereb Cortex10, 464–472.
41.
ResnickSM, PhamDL, KrautMA, ZondermanAB, DavatzikosC (2003) Longitudinal magnetic resonance imaging studies of older adults: A shrinking brain. J Neurosci23, 3295–3301.
42.
GoldszalAF, DavatzikosC, PhamDL, YanMX, BryanRN, ResnickSM (1998) An image-processing system for qualitative and quantitative volumetric analysis of brain images. J Comput Assist Tomogr22, 827–837.
43.
ShenD, DavatzikosC (2002) HAMMER: Hierarchical attribute matching mechanism for elastic registration. IEEE Trans Med Imaging21, 1421–1439.
44.
DriscollI, DavatzikosC, AnY, WuX, ShenD, KrautM, ResnickSM (2009) Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology72, 1906–1913.
45.
PengasG, PereiraJM, WilliamsGB, NestorPJ (2009) Comparative reliability of total intracranial volume estimation methods and the influence of atrophy in a longitudinal semantic dementia cohort. J Neuroimaging19, 37–46.
46.
Beason-HeldLL, KrautMA, ResnickSM (2008) I. Longitudinal changes in aging brain function. Neurobiol Aging29, 483–496.
47.
HartleyHO, RaoJN (1967) Maximum-likelihood estimation for the mixed analysis of variance model. Biometrika54, 93–108.
48.
SimpsonBN, KimM, ChuangYF, Beason-HeldL, Kitner-TrioloM, KrautM, LiretteST, WindhamBG, GriswoldME, Legido-QuigleyC, ThambisettyM (2016) Blood metabolite markers of cognitive performance and brain function in aging. J Cereb Blood Flow Metab36, 1212–1223.
49.
MendisDB, IvyGO, BrownIR (1996) SC1, a brain extracellular matrix glycoprotein related to SPARC and follistatin, is expressed by rat cerebellar astrocytes following injury and during development. Brain Res730, 95–106.
50.
WeimerJM, StancoA, ChengJG, VargoAC, VooraS, AntonES (2008) A BAC transgenic mouse model to analyze the function of astroglial SPARCL1 (SC1) in the central nervous system. Glia56, 935–941.
51.
XuPT, LiYJ, QinXJ, ScherzerCR, XuH, SchmechelDE, HuletteCM, ErvinJ, GullansSR, HainesJ, Pericak-VanceMA, GilbertJR (2006) Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. Neurobiol Dis21, 256–275.
52.
KlingbergT, KawashimaR, RolandPE (1996) Activation of multi-modal cortical areas underlies short-term memory. Eur J Neurosci8, 1965–1971.
53.
KlingbergT (1998) Concurrent performance of two working memory tasks: Potential mechanisms of interference. Cereb Cortex8, 593–601.
54.
SaloE, RinneT, SalonenO, AlhoK (2013) Brain activity during auditory and visual phonological, spatial and simple discrimination tasks. Brain Res1496, 55–69.
55.
GradyCL, McIntoshAR, RajahMN, BeigS, CraikFI (1999) The effects of age on the neural correlates of episodic encoding. Cereb Cortex9, 805–814.
56.
MaddenDJ, GottlobLR, AllenPA (1999) Adult age differences in visual search accuracy: Attentional guidance and target detectability. Psychol Aging14, 683–694.
57.
Beason-HeldLL, GohJO, AnY, KrautMA, O’BrienRJ, FerrucciL, ResnickSM (2013) Changes in brain function occur years before the onset of cognitive impairment. J Neurosci33, 18008–18014.
58.
SepulcreJ, SabuncuMR, BeckerA, SperlingR, JohnsonKA (2013) In vivo characterization of the early states of the amyloid-beta network. Brain136, 2239–2252.
59.
JohnsonKA, SchultzA, BetenskyRA, BeckerJA, SepulcreJ, RentzD, MorminoE, ChhatwalJ, AmariglioR, PappK, MarshallG, AlbersM, MauroS, PepinL, AlverioJ, JudgeK, PhiliossaintM, ShoupT, YokellD, DickersonB, Gomez-IslaT, HymanB, VasdevN, SperlingR (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol79, 110–119.
RudyCC, HunsbergerHC, WeitznerDS, ReedMN (2015) The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer’s disease. Aging Dis6, 131–148.
